




Foxberry Medical Cannabis & Life Sciences Index Rules

Foxberry Ltd
24th January, 2020



FOXBERRY LTD IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY

© 2020 FOXBERRY LTD. ALL RIGHTS RESERVED

Disclaimer

This document has been prepared by Foxberry Ltd (“**Foxberry**”, “**we**”, “**us**”, “**our**”). This document is subject to the copyright of Foxberry. The information contained herein is believed to be accurate in all respects, but no representation or warranty, expressed or implied, as to its accuracy or completeness is made by any party. Nothing herein should be relied upon as a promise or representation as to the future. Nothing herein constitutes financial or investment advice. Past performance is no guide to future performance.

Foxberry disclaims all and any liability whatsoever with respect to, and makes no representation or warranty regarding the accuracy or completeness of the Index Rules or that such Index Rules are current. Foxberry retains the right to change the Index Rules in accordance with its provisions and such Index Rules may change at any time.

This document is not intended for distribution to, or use by, any person or entity in any jurisdiction where such distribution or use would be contrary to law or regulation and must not be distributed to any other person or replicated in any form without the prior written consent of Foxberry. In particular, these materials are not intended for distribution to any person in the United States or to or for the account of any “**U.S. person**”, as defined in Regulation S under the Securities Act of 1933, as amended.

Foxberry Ltd is authorised and regulated by the Financial Conduct Authority (number 677250). Foxberry Ltd is incorporated in England and Wales (number 09278597), with its registered office address at Level 39, One Canada Square, Canary Wharf, London, E14 5AB, United Kingdom.

Contents

1	Introduction	4
1.1	Objective	4
1.2	This document	4
1.3	Index coverage	5
2	Background	6
2.1	Medical Cannabis & Life Sciences	6
2.1.1	The cannabis plant	6
2.1.2	Medical use	6
2.2	New Frontier Data	7
2.2.1	Source	7
2.2.2	Introduction	7
2.2.3	About	7
2.2.4	Further information	7
2.2.5	The industry database	8
2.2.5.1	Overview	8
2.2.5.2	Inclusion criteria	8
2.2.5.3	Data gathering process	9
2.2.5.4	Sector classification	9
2.2.5.5	Delivery	12
2.3	Liquidity-weighted indices	12
3	Methodology	14
3.1	Overview	14
3.2	Composition	14
3.2.1	Overview	14
3.2.2	Selection	14
3.2.2.1	Ordinary selection	14
3.2.2.2	Potential monthly re-allocation	15
3.2.3	Weighting	15
3.2.4	RGMC Exclusion List	16
3.3	Calculation	16
3.4	Definitions	16

3.4.1	General definitions	16
3.4.2	Index specific definitions	17
3.4.2.1	Identifiers	17
3.4.2.2	Calculation related	17
3.4.2.3	Calendar related	17
3.4.2.4	Selection related	18
3.5	Calculation	18
4	Index Specifics	19
4.1	Overview	19
4.2	Medical Cannabis & Life Sciences USD Net Total Return Index	19
4.2.1	Introduction	19
4.2.2	Methodology summary	19
4.2.3	Definitions	20
4.2.3.1	Identifiers	20
4.2.3.2	Calculation related	20
4.2.3.3	Calendar related	20
4.2.3.4	Selection related	21
4.3	Medical Cannabis & Life Sciences USD Price Return Index	21
4.3.1	Introduction	21
4.3.2	Methodology summary	21
4.3.3	Definitions	21
4.3.3.1	Identifiers	22
4.3.3.2	Calculation related	22
4.3.3.3	Calendar related	22
4.3.3.4	Selection related	23
	Bibliography	24
	Document Catalogue	25

1 Introduction

1.1 Objective

The objective of each Index in the Medical Cannabis & Life Sciences family (the “**Family**”) is to provide exposure to the stocks of publicly-traded companies listed on eligible exchanges, which are involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors, as determined by the Thematic Industry Expert, but excluding companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market, as determined by Rize in accordance with the RGMC Exclusion List Methodology.

The exact specification of each Index is detailed in chapter 4.

1.2 This document

This document comprises the rules (the “**Index Rules**”) of the Foxberry Medical Cannabis & Life Sciences indices listed in section 1.3 (each an “**Index**”), a notional rule-based proprietary index owned by Foxberry in its capacity as index owner (the “**Index Owner**”) and index administrator (the “**Index Administrator**”) of the Index.

This document only details certain specifics of each relevant Index. This document should be read in conjunction with the following documents:

- the “Foxberry Equity Cash Index Methodology” document (the “**Cash Methodology**”); *and*
- the “Rize Global Medical Cannabis Exclusion List Methodology” document (the “**RGMC Exclusion List Methodology**”)

1.3 Index coverage

As of the date of this document, the following Indices form part of the Family and are covered by this document:

- Foxberry Medical Cannabis & Life Sciences USD Net Total Return Index
- Foxberry Medical Cannabis & Life Sciences USD Price Return Index

Specific attributes of these Indices are detailed in chapter 4.

2 Background

2.1 Medical Cannabis & Life Sciences

2.1.1 The cannabis plant

Cannabis is a genus of flowering plants in the Cannabaceae family, with at least three commonly recognised species: *Cannabis sativa*, *Cannabis indica*, and *Cannabis ruderalis*. Cannabis is believed to have originated from central or south Asia.¹

The cannabis plant has been used to create a range of products. The cannabis plants produce a group of chemicals called cannabinoids, which produce mental and physical effects when consumed, including the non-psychoactive CBD and the psychoactive THC, which has led it to also have had medical uses as detailed in section 2.1.2.²

2.1.2 Medical use

Due to its cannabinoids, cannabis has a history of having been used for its medical purposes and cannabis extracts were listed in the British and US Pharmacopeia (1840) for sedative and anticonvulsant effect, but within a century these were removed due to the risks of abuse and intoxication as newer, more targeted, effective pure drugs that were prescribed at known and reliable doses took their place.³

In recent years, the acceptance of the use of cannabis for medical purposes has increased, as indicated by changes in legislation regarding cannabis uses across the world such as the 2018 Farm Bill in the US and Bill C-45 in Canada. The use of cannabis as a source for new medicine has been driven by inadequate relief of current approaches for a number of chronic diseases or symptoms including Multiple Sclerosis, Crohn's disease, Alzheimer's disease, cancer and chronic pain.⁴

¹Wikipedia, 2019.

²Wikipedia, 2019.

³Madras, 2015.

⁴Madras, 2015.

2.2 New Frontier Data

2.2.1 Source

The source for all information in this section 2.2 is New Frontier Data and was validated by New Frontier Data as correct as of the 27 November 2019. For current information, readers are directed to New Frontier Data and their website.

2.2.2 Introduction

Frontier Financial Group Inc. (trading as “**New Frontier Data**”) is the “**Thematic Industry Expert**”.

As a young and emerging industry, the legal cannabis industry is a fast moving and ever changing industry and as such the market continues to be plagued by fragmented data, ambiguity of information and a consequent lack of transparency.

New Frontier Data has therefore created a centralised data repository, similar to what is generally available for more established industries, for both timely and accurate research and analysis.

2.2.3 About

New Frontier Data is an independent, technology-driven analytics company specialising in the cannabis industry. Its big data engine ingests, normalises, and provides real time access to billions of data points across hundreds of data sets worldwide, supporting responsible, reliable, and statistically meaningful research and analysis. New Frontier Data offers comprehensive industry data, actionable intelligence, and custom advisory services to investors and organisations, both inside and outside of the cannabis industry. New Frontier Data’s services support strategic planning, market entry and positioning, investing, socioeconomic understanding, and public policy decision-making.

New Frontier Data’s reports and data have been cited in over 82 countries around the world to inform industry leaders. The New Frontier Data team is comprised of analysts, economists, data scientists, and researchers who operate across 3 continents. The company is headquartered in Washington D.C. (US) with additional offices in Denver (US), London (UK), and Sao Paulo (Brazil).

2.2.4 Further information

Further information about New Frontier Data can be found on its official website at <https://newfrontierdata.com>.

2.2.5 The industry database

2.2.5.1 Overview

New Frontier Data has created and maintains the New Frontier Data Industry Database (the “**Industry Database**”) of public companies across the globe that have a significant or distinct proportion of their revenues derived from, and/or a significant or distinct proportion of their expenditure associated with the global cannabis industry. The Industry Database has over 4 years of history and is designed to capture the full spectrum of cannabis-focused businesses and ancillary activities. As of the 28 October 2019, the Industry Database contained 295 companies.

2.2.5.2 Inclusion criteria

To qualify for inclusion into the Industry Database, a potential company must:

- be a public company;
- be domiciled in a jurisdiction where public filings and disclosures of its business activities are required and accessible;
- fall into one of the seven Sector Classifications as defined in section 2.2.5.4; *and*
- have exposure to cannabis-related businesses activities, as per the following:
 - a significant or distinct proportion of its operating revenues derived from cannabis-related business activities. Such activities may vary, from the sale of agri-tech equipment, to financing solutions. As a rule, there is generally no more than one degree of separation between a company and the cannabis industry. For example, a company producing carbon dioxide enrichment systems for greenhouse growers would be included, whereas producers from which such company buys its system sub-components would be excluded; *and/or*
 - a significant or distinct proportion of its expenditures associated with cannabis-related business activities. This criterion is in place to capture companies that fall into one or more of the following categories:
 1. companies that are start-up ventures;
 2. companies that are awaiting revenue growth post investment, research and development, regulatory approvals and/or clinical trials; *and*

3. companies that are in the process of pivoting into the cannabis space.

New Frontier Data does not accept payment from companies or third parties to be included in the Industry Database.

2.2.5.3 Data gathering process

New Frontier Data consolidates data from a variety of partners, providers and exchanges. The raw data collected is reviewed and non-cannabis related companies are systematically excluded. The remaining companies are then subject to New Frontier Data's inclusion criteria and business activity reviews, information in respect of which is collected through a combination of direct company engagement and a review of public filings and disclosures (including but not limited to all press releases, audited and unaudited financial statements, directors' reports and management's public statements).

2.2.5.4 Sector classification

The Industry Database is subdivided into seven sector classifications (each a "**Sector**" or "**Sector Classification**") which each reflect a unique segment of the cannabis industry. The classification methodology is a first-of-its-kind, benchmark methodology for identifying, segmenting and mapping public companies in the global cannabis space. The Sector Classifications are designed for the investment and research communities, with the aim of helping identify, define and unpack the Sectors within the cannabis industry that best reflect the overall industry structure and its growth prospects. The Sector Classifications are described below:

Biotechnology/Pharma Companies in this Sector have a significant proportion of their revenues derived from, and/or a significant proportion of their expenditures associated with the research of cannabinoids, the endocannabinoid system and the development and sale of medical cannabis and/or pharmaceutical products that treat a variety of medical symptoms and conditions. Such companies use synthetic or biological processes, organisms, cells or cellular components to create new medical breakthroughs and technologies, or to improve old ones. Companies in this category may engage in a variety of activities but many will have a strong research and development focus on activities such as new delivery methods, novel formulations, patent generation, and similar end-goals which have medical applications.

This Sector also includes vertically-integrated companies which cultivate cannabis and/or produce and sell cannabis and/or cannabis-derived products predominantly for medical / therapeutic use, biotech research and/or the production of pharmaceutical products. However, unless the relevant companies cultivate cannabis and/or produce

and sell cannabis and/or cannabis-derived products predominantly for medical / therapeutic use, biotech research and/or the production of pharmaceutical products, they will be classified under the Cultivation and Retail Sector, even if a significant proportion of their revenues or expenditures relate to the Biotechnology/Pharma Sector.

This is the largest cannabis Sector in the US and is gaining attention as governments, universities and private companies invest more into researching cannabinoids, the endocannabinoid system and the potential of cannabis-derived medications.

Big Pharma For the most part, Big Pharma has watched the industry from the sidelines, but is now recognising that further legalization of cannabis and cannabis-derived products for medical / therapeutic use and pharmaceutical products may challenge their bottom lines. Accordingly, companies in this Sector are “Big Pharma” companies that are making forays into the Sector through the development or acquisition of patents, distribution partnerships and sponsored clinical trials and therefore have a distinct, but not necessarily significant, proportion of their revenues derived from and/or a distinct, but not necessarily significant, proportion of their expenditures associated with the global cannabis industry. Many anticipate that Big Pharma will inevitably enter the space more directly in the near future. Such moves would further accelerate public understanding and confidence in the use and application of cannabis and cannabis-derived products for medical / therapeutic use and pharmaceutical products.

Hemp & CBD Companies in this Sector are primarily involved in the industrial application of hemp, and/or in the retail consumer CBD market geared toward sectors such as health and wellness. Hemp (sometimes referred to as “industrial hemp”) is a strain of the Cannabis sativa plant that is defined as cannabis with less than 0.30% THC. Hemp has a higher concentration of CBD. Hemp has myriad commercial applications that include but are not limited to paper, textiles, clothing, biofuel, biodegradable plastics, building materials, car parts, food and beverages.

Agriculture Tech & Supplies Companies in this Sector use modern technologies to increase cannabis yields or enhance the quality of the plant. These technologies include automated growing systems, greenhouses, farming products, nutrients, hydroponics, fertilisation systems, information technology, soils, temperature and moisture sensors, aerial images and GPS technology. These systems can help reduce the impact of natural ecosystems, increase worker safety and decrease the need to use water, fertiliser and pesticides.

Ancillary Products Companies in this Sector provide a variety of in-fused cannabis products including, but not limited to, food products, drinks, oils, extracts, lotions and other topicals. Other products may include consumption devices such as glass pieces, pre-rolls, handheld vaporisers, desktop vaporisers and inhalers. Companies in this Sector may also specialise in extraction technologies.

Ancillary Services Companies in this Sector perform myriad services and provide necessary support solutions to cannabis companies. This Sector includes companies that specialise in plant-touching services related to the extraction and purification of cannabinoids for use in branded consumer products and/or medical products. This includes companies that are focused on investing, acquiring or merging with businesses in the cannabis industry. This Sector also includes holding companies that own and/or manage portfolios of cannabis companies. Companies in this Sector may also run cannabis medical clinics, dispensaries and hospitality and tourism services. They may also offer professional services such as branding, packaging, physical security, transportation, lab testing, distribution, and insurance. Companies in this Sector also provide professional consulting support services to improve business performance, efficiency and management. Other companies in this Sector provide technological support to cannabis companies in the form of delivery services, enterprise software, e-commerce platforms, communication services, mapping services, trading platforms and seed-to-sale systems to track cannabis from cultivation to sale. Companies in this Sector also help cannabis companies improve their social media presence and online content delivery. Due to US federal laws that force cannabis companies to mainly use only cash currency there is a great need for physical security to protect liquid assets as well as the cultivated product and/or derivatives thereof. As such, this Sector may also include companies that specialise in electronic surveillance, cash and product tracking, IT services, and asset protection. There is also a special need in the cannabis industry for real estate support services to find locations to cultivate cannabis on a large scale. There is a high degree of difficulty in finding, acquiring, and managing commercial real estate for legal cannabis companies. This has led to the creation of companies specialising in commercial real estate, and who have built up the expertise to navigate local cannabis regulation and licensing laws.

Cultivation & Retail Companies in this Sector are mainly vertically-integrated companies that grow and sell cannabis directly to consumers, or dispensary operators who purchase product to on-sell to consumers. Currently, Canadian companies with Canadian federal licenses dominate this Sector. Despite the US market having wildly

varying laws from one state to the next, companies in the US are increasingly beginning to list on the OTC market.

Cultivation & Retail makes up one of the largest Sector within the emerging legal cannabis industry. The vast majority of companies in this Sector are involved in cultivation, processing, packaging, retail as well as various other stages of the supply chain. Whilst some companies may state that they operate within the medicinal sector, many are materially involved in, or may over time become materially involved in, the recreational sector as well. However, unless the relevant companies cultivate cannabis and/or produce and sell cannabis and/or cannabis-derived products predominantly for medical / therapeutic use, biotech research and/or the production of pharmaceutical products, they will be classified under the Cultivation & Retail Sector, even if a significant proportion of their revenues or expenditures relate to the Biotechnology/Pharma Sector. This Sector may also include large holding companies which own majority stakes in Cultivation & Retail subsidiaries, but otherwise have no operations of their own.

2.2.5.5 Delivery

New Frontier Data extracts and delivers to the Index Administrator the Industry Database (which include the Sector Classifications) semi-annually with respect to each Selection Day.

In addition, with respect to each Potential Selection Day, New Frontier Data will deliver the Industry Database if any company within the Industry Database has been re-allocated to the Cultivation & Retail Sector.

2.3 Liquidity-weighted indices

The most common type of weighting methodology of an index is the market-capitalisation weighted index, where the weight of each constituent in the index is weighted proportionally to a measure of its market-capitalisation (subject to any weight restrictions).

In a liquidity-weighted index, the weights of each constituent is proportional to its average daily trading volume (measured in a specific currency over a specific time period), potentially subject to any weight restrictions.

Weighting by liquidity in this manner can be useful when the potential constituents may be stocks with a low market-capitalisation and/or a low average daily trading volume, or when the relationship between the market-capitalisation and average daily trading volume of the potential constituents is not strong.

Weighting the constituents by their relative liquidity in this manner, ensures that (subject to any potential weight restrictions) a constituent

with larger liquidity than another constituent also has a larger weight in the index.

3 Methodology

3.1 Overview

This chapter describes the methodology of the Index and covers among other things the methodology for determining the composition of the Index, which is detailed in section 3.2. The exact specification of each Index is available in chapter 4.

3.2 Composition

3.2.1 Overview

The Index conducts its ordinary rebalance, when a new Composition of the Index is determined, semi-annually as described in section 3.2.2.1.

In addition, the Index may potentially conduct an additional rebalance in other months if a Constituent has been re-allocated to the Cultivation & Retail Sector, as indicated by the Thematic Industry Expert and detailed in section 3.2.2.2

3.2.2 Selection

3.2.2.1 Ordinary selection

The ordinary selection of stocks for each Index is conducted with respect to each Selection Day in accordance with the below process in which each step more and more stocks are potentially excluded:

1. all stocks in the Underlying Universe are considered for inclusion;
2. stocks which are listed on a Eligible Exchange are considered further for inclusion;
3. stocks, which according to the Thematic Industry Expert and the relevant data feed have been classified within one of the following Sectors are included: Biotechnology/Pharma, Big Pharma, Hemp & CBD and Agriculture Tech & Supplies (each an “**Included Sector**”);
and

4. stocks which are listed on the RGMC Exclusion List (as described in section 3.2.4) are excluded; *and*
5. on and following the 13 December 2019, companies with a market capitalisation of less than USD 30mm are excluded; *and*
6. on and following the 13 December 2019, stocks with a 3-month USD equivalent daily average volume of less than USD 100k are excluded.

After this process is complete, the remaining stocks together form the “**Composition**” of the Index (each such stock being a “**Constituent**”).

With regards to Selection Dates prior to the Live Calculation Date, the following Composition have been used: (i) prior to the 13 December 2019: a fixed Underlying Universe provided by the Thematic Industry Expert on the 28 October 2019 has been used; *and* (ii) on and after the 13 December 2019: an extraordinary rebalance of the Index based on a Selection Day and Rebalancing Day as of the 13 December 2019 has been conducted.

3.2.2.2 Potential monthly re-allocation

In addition to the process described in 3.2.2.1, a process may potentially also be conducted with respect to each Potential Selection Day.

With respect to each Potential Selection Day, if the Thematic Industry Expert indicates that a Constituent has been re-allocated to the Cultivation & Retail Sector, this will trigger a removal of such Constituent from the Composition on the immediately following Potential Rebalancing Day, and the weight of the removed Constituent(s) will be spread proportionally across the remaining Constituents.

3.2.3 Weighting

The weighting of each Constituent is calculated in accordance with the below methodology:

1. Each Constituent belonging in the Big Pharma Sector is given a weight equal to 10% divided by the total number of Constituents belonging in the Big Pharma Sector.
2. Each Constituent not belonging in the Big Pharma Sector is given a weight equal to 90% times the 3-month USD equivalent daily average volume of such Constituent divided by the total 3-month USD equivalent daily average volume for all Constituents not belonging in the Big Pharma Sector.
3. A weight cap is applied for each Constituent not belonging in the Big Pharma Sector by re-distributing any weight which is larger than 15% to the other Constituents not belonging in the Big Pharma Sector proportionally in an iterative manner.

4. For all Constituents, following the application of the weight cap, a weight floor of 0.05% is applied by proportionally re-distributing any weight larger than the weight floor to the relevant Constituents in an iterative manner.

The Index rebalances periodically and ordinarily takes place on the Rebalancing Day.

3.2.4 RGMC Exclusion List

The Rize Global Medical Cannabis Exclusion List (the “**RGMC Exclusion List**”) has been created and is maintained by Rize ETF Limited (“**Rize**”). The purpose of the RGMC Exclusion List is to act as a non-exhaustive screen for companies operating within the global medical cannabis and life sciences sector that are determined by Rize to be:

1. non-compliant with either state or federal laws in the countries in which they operate; *and/or*
2. directly involved in the production and/or distribution of cannabis flower and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market (including the provision of plant-touching services, such as extraction and purification services, to the foregoing companies).

The RGMC Exclusion List Methodology formally documents the process and governance associated with the construction and maintenance of the RGMC Exclusion List and is available here: www.rizeetf.com.

3.3 Calculation

Calculation of the Index based on its Composition is defined in the Cash Methodology.

3.4 Definitions

In addition to the specific definitions defined in the relevant section in chapter 4, the following key terms and definitions are defined:

3.4.1 General definitions

Index Level means with respect to a certain date, the level of the Index as determined in accordance with the methodology described in this document and any related documents.

3.4.2 Index specific definitions

The following definitions are specific to each Index. The purpose of the below is to serve as a summary of these definitions and they shall be read in conjunction with the specific definitions for each Index which are detailed in the the relevant section of chapter 4.

3.4.2.1 Identifiers

Index Name means the name of the Index.

Foxberry Ticker means the Foxberry ticker identifier of the Index.

Bloomberg Ticker means the Bloomberg ticker identifier of the Index.

Reuters RIC means the Reuters RIC identifier of the Index.

WKN means the WKN identifier of the Index.

ISIN means the ISIN identifier of the Index.

3.4.2.2 Calculation related

Index Calculator means any affiliate, subsidiary or third party designated by the Index Administrator that will act as calculation agent in connection with the Index. The identity of the Index Calculator, if applicable, is detailed for each Index in the relevant section in chapter 4.

Dividend Treatment means the type of dividend treatment of the Index, which can be (i) price return; (ii) gross total return; *or* (iii) net total return.

Corporate Actions Methodology means the methodology used to adjust for certain corporate actions as defined in the Cash Methodology, which can be (i) standard; *or* (ii) divisor.

Weighting Methodology means the weighting methodology used to determine the weight of each Constituent.

3.4.2.3 Calendar related

Index Business Day means each day for which the level of the Index is calculated

Live Calculation Date means the the date on which the Index Calculator started to publicly disseminate the Index Levels of the Index.

Live Methodology Date means the date on which the Index Administrator had finalised the algorithm of the Index.

Selection Day means each periodic date from which data is used to determine the Composition of the Index for each ordinary rebalance.

Potential Selection Day means each periodic date from which data is used to determine if an additional rebalance should take place, and in such cases from which data is used to determine the Composition of the Index.

Rebalancing Day means each periodic date on which the Index ordinary rebalances and adjusts its Composition.

Potential Rebalancing Day means each periodic date on which the Index may rebalance and adjust its Composition for each potential additional rebalance.

Rebalancing Month means each of the months on which the relevant Index rebalances its Composition.

Potential Rebalancing Month means each of the months on which the relevant Index potentially has an additional rebalance of its Composition.

3.4.2.4 Selection related

Underlying Universe: means an underlying universe of potential stocks which will be used as a starting point to determine the Composition of the Index.

Eligible Exchange means each exchange on which a listing would be eligible for inclusion in the Underlying Universe.

3.5 Calculation

The Index is calculated and disseminated by the Index Calculator with regards to each Index Business Day. Calculation of the Index based on its Constituents is detailed in the document Cash Methodology.

4 Index Specifics

4.1 Overview

This chapter describes the specific attributes with respect to each Medical Cannabis & Life Sciences Index listed in section 1.3.

4.2 Medical Cannabis & Life Sciences USD Net Total Return Index

4.2.1 Introduction

For the purposes of this section 4.2 and all subsections thereof, the Index shall refer to the Foxberry Medical Cannabis & Life Sciences USD Net Total Return Index.

4.2.2 Methodology summary

The Index offers exposure to publicly-traded companies listed on eligible exchanges, which are involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors, as determined by the Thematic Industry Expert, but excluding companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market, as determined by Rize in accordance with the RGMC Exclusion List Methodology. The Index includes companies which are listed on an Eligible Exchange semi-annually (subject to potential additional monthly rebalances) rebalanced net total return index denominated in USD. Excluding companies in the Big Pharma sector which are equally weighted at a fixed weight of 10% for the sector, the Index is a liquidity-weighted index with its weights based on the 3-month USD equivalent daily average volume (subject to a minimum weight per stock of 0.05% and a maximum weight per stock at the point of weight determination of 15%).

4.2.3 Definitions

4.2.3.1 Identifiers

Index Name means Foxberry Medical Cannabis & Life Sciences USD Net Total Return Index.

Foxberry Ticker means medical_cannabis_life_sciences_tr.

Bloomberg Ticker means FXBYFLWR Index.

Reuters RIC means .FXBYFLWR.

WKN means SLA99X.

ISIN means DE000SLA99X8.

4.2.3.2 Calculation related

Index Calculator means Solactive AG.

Dividend Treatment means net total return.

Corporate Actions Methodology means divisor.

4.2.3.3 Calendar related

Index Business Day means each weekday Monday-Friday.

Live Calculation Date means the 24 January 2020.

Live Methodology Date means the 24 January 2020.

Rebalancing Month means each of the months of March and September.

Potential Rebalancing Month means each of the months of January, February, April, May, June, July, August, October, November, December.

Selection Day means the first Friday of each Rebalancing Month.

Potential Selection Day means the first Friday of each Potential Rebalancing Month.

Rebalancing Day means the third Friday of each Rebalancing Month.

Potential Rebalancing Day means the third Friday of each Potential Rebalancing Month.

4.2.3.4 Selection related

Underlying Universe: means, with respect to each Selection Day, the most recently provided list of stocks in the Industry Database, including the list expected to be received with respect to the relevant Selection Day.

Eligible Exchange means each of the following exchanges: ASE, Hong Kong SE, NASDAQ, NASDAQ CM, NASDAQ GM, NASDAQ GS, NYSE, NYSEAmerican, New York, Toronto, Venture.

4.3 Medical Cannabis & Life Sciences USD Price Return Index

4.3.1 Introduction

For the purposes of this section 4.3 and all subsections thereof, the Index shall refer to the Foxberry Medical Cannabis & Life Sciences USD Price Return Index.

4.3.2 Methodology summary

The Index offers exposure to publicly-traded companies listed on eligible exchanges, which are involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors, as determined by the Thematic Industry Expert, but excluding companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market, as determined by Rize in accordance with the RGMC Exclusion List Methodology. The Index includes companies which are listed on an Eligible Exchange semi-annually (subject to potential additional monthly rebalances) rebalanced price return index denominated in USD. Excluding companies in the Big Pharma sector which are equally weighted at a fixed weight of 10% for the sector, the Index is a liquidity-weighted index with its weights based on the 3-month USD equivalent daily average volume (subject to a minimum weight per stock of 0.05% and a maximum weight per stock at the point of weight determination of 15%).

4.3.3 Definitions

4.3.3.1 Identifiers

Index Name means Foxberry Medical Cannabis & Life Sciences USD Price Return Index.

Foxberry Ticker means medical_cannabis_life_sciences_pr .

Bloomberg Ticker means FXBYFLWP Index.

Reuters RIC means .FXBYFLWP.

WKN means SLA99W.

ISIN means DE000SLA99W0.

4.3.3.2 Calculation related

Index Calculator means Solactive AG.

Dividend Treatment means price return.

Corporate Actions Methodology means divisor.

4.3.3.3 Calendar related

Index Business Day means each weekday Monday-Friday.

Live Calculation Date means the 24 January 2020.

Live Methodology Date means the 24 January 2020.

Rebalancing Month means each of the months of March and September.

Potential Rebalancing Month means each of the months of January, February, April, May, June, July, August, October, November, December.

Selection Day means the first Friday of each Rebalancing Month.

Potential Selection Day means the first Friday of each Potential Rebalancing Month.

Rebalancing Day means the third Friday of each Rebalancing Month.

Potential Rebalancing Day means the third Friday of each Potential Rebalancing Month.

4.3.3.4 Selection related

Underlying Universe: means, with respect to each Selection Day, the most recently provided list of stocks in the Industry Database, including the list expected to be received with respect to the relevant Selection Day.

Eligible Exchange means each of the following exchanges: means each of the following exchanges: ASE, Hong Kong SE, NASDAQ, NASDAQ CM, NASDAQ GM, NASDAQ GS, NYSE, NYSEAmerican, New York, Toronto, Venture.

Bibliography

- Madras, Bertha K. (2015). *Update of Cannabis and its medical use*. URL: https://www.who.int/medicines/access/controlled-substances/6_2_cannabis_update.pdf.
- Wikipedia (June 2019). *Cannabis*. URL: <https://en.wikipedia.org/wiki/Cannabis>.

Document Catalogue

Bloomberg Ticker, 17

Cash Methodology, 4
Composition, 15
Constituent, 15
Corporate Actions Methodology, 17

Dividend Treatment, 17

Eligible Exchange, 18

Family, 4
Foxberry, 1
Foxberry Ticker, 17

Included Sector, 14
Index, 4
Index Administrator, 4
Index Business Day, 17
Index Calculator, 17
Index Level, 16
Index Name, 17
Index Owner, 4
Index Rules, 4
Industry Database, 8
ISIN, 17

Live Calculation Date, 17
Live Methodology Date, 17

New Frontier Data, 7

Potential Rebalancing Day, 18
Potential Rebalancing Month, 18
Potential Selection Day, 18

Rebalancing Day, 18
Rebalancing Month, 18
Reuters RIC, 17
RGMC Exclusion List, 16
RGMC Exclusion List Methodology, 4
Rize, 16

Sector, 9
Sector Classification, 9
Selection Day, 18

Thematic Industry Expert, 7

U.S. person, 1
Underlying Universe, 18

Weighting Methodology, 17
WKN, 17